These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 30018408)

  • 1. AR-V7 detection guides treatment.
    Romero D
    Nat Rev Clin Oncol; 2018 Sep; 15(9):533. PubMed ID: 30018408
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Oct; 196(4):1124. PubMed ID: 27628794
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical decision-making with AR-V7.
    Thoma C
    Nat Rev Urol; 2019 Dec; 16(12):694. PubMed ID: 31690843
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO].
    Rexer H; Hammerer P; Schostak M; König F
    Urologe A; 2017 Dec; 56(12):1615-1617. PubMed ID: 29071394
    [No Abstract]   [Full Text] [Related]  

  • 5. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
    Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
    Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Crumbaker M; Savdie R; Joshua AM
    Eur Urol; 2018 May; 73(5):736-737. PubMed ID: 29162351
    [No Abstract]   [Full Text] [Related]  

  • 9. Has the PROPHECY of AR-V7 Been Fulfilled?
    De Laere B; Ost P; Grönberg H; Lindberg J
    J Clin Oncol; 2019 Aug; 37(24):2181-2182. PubMed ID: 31265360
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance.
    Fenner A
    Nat Rev Urol; 2016 Dec; 13(12):695. PubMed ID: 27779227
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Cronauer MV; Merseburger AS; Hoda MR
    Eur Urol; 2017 Apr; 71(4):e105-e106. PubMed ID: 27663049
    [No Abstract]   [Full Text] [Related]  

  • 12. AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?
    Montgomery RB; Plymate SR
    JAMA Oncol; 2016 Nov; 2(11):1450-1451. PubMed ID: 27261766
    [No Abstract]   [Full Text] [Related]  

  • 13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
    García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
    Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AR-v7 liquid biopsy for treatment stratification in prostate cancer: how close are we?
    Fletcher C
    Curr Opin Urol; 2017 Sep; 27(5):500-509. PubMed ID: 28590268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
    Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
    [No Abstract]   [Full Text] [Related]  

  • 17. Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods.
    Bernemann C; Steinestel J; Humberg V; Bögemann M; Schrader AJ; Lennerz JK
    BJU Int; 2018 Aug; 122(2):219-226. PubMed ID: 29359890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
    Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
    Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
    J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.